Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vicente Lago

Gastroenterology Miami, FL Medical Doctor

NPI 1619068095 CMS profile 254773

351 Nw 42Nd Ave, Suite 305, Miami, FL 33126

Open in the dashboard

General payments

$9,512

529 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vicente Lago of Miami, FL is reported in the CMS Open Payments database as having received $9,512 across 529 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,274 63
2024 General $1,651 82
2023 General $1,313 73
2022 General $1,565 80
2021 General $1,400 88
2020 General $1,057 64
2019 General $1,252 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vicente Lago
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Vicente Lago were reported at $1,274. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Vicente Lago Gastroenterology median Middle half National median
2019 $1,252 $417 $126–$1,100 $163
2020 $1,057 $224 $74–$624 $114
2021 $1,400 $352 $106–$1,054 $132
2022 $1,565 $448 $129–$1,270 $149
2023 $1,313 $533 $150–$1,390 $160
2024 $1,651 $605 $160–$1,606 $164
2025 $1,274 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,696 116 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,493 111 payments
  3. QOL Medical, LLC $1,435 99 payments
  4. Ironwood Pharmaceuticals, Inc $402 24 payments
  5. Madrigal Pharmaceuticals $368 13 payments
  6. Phathom Pharmaceuticals, Inc. $326 15 payments
  7. Ardelyx, Inc. $304 15 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $283 14 payments
  9. Nestle HealthCare Nutrition Inc. $274 14 payments
  10. Janssen Biotech, Inc. $240 14 payments
  11. Other $1,692 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,506 528 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. CREON $1,342 53 payments
  2. XIFAXAN $1,319 96 payments
  3. LINZESS $1,041 61 payments
  4. Sucraid Therapy For Csid $723 48 payments
  5. Sucraid Therapy For Csid $522 38 payments
  6. RINVOQ $454 25 payments
  7. SKYRIZI $401 18 payments
  8. ZENPEP $367 18 payments
  9. VIBERZI $353 20 payments
  10. STELARA $327 13 payments
  11. Other $4,454 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,250

Median for Gastroenterology: 569

Drug cost

$348,177

Median for Gastroenterology: $104,976

Branded share of claims

35.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 43 $98,211
Linzess Linaclotide Brand 99 $78,529
Creon Lipase/Protease/Amylase Brand 19 $51,239
Viberzi Eluxadoline Brand 27 $33,362
Trulance Plecanatide Brand 30 $25,326
Mesalamine Generic 25 $17,934
Voquezna Vonoprazan Fumarate Brand 15 $10,957
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 106 $6,272
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 35 $6,146
Dexlansoprazole Dr Dexlansoprazole Brand 19 $5,583

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$22,624

Medicare's payments for the services billed

Medicare patients

109

Average age 79

Services billed

223

68 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 50%
Depression 50%
Chronic kidney disease 44%
Ischemic heart disease 41%
COPD 34%
Alzheimer's or dementia 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $354
$354 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $268
$268 15 —
CREON
  • AbbVie, Inc. $260
$260 19 —
LINZESS
  • AbbVie, Inc. $111
  • Ironwood Pharmaceuticals, Inc $49
$160 99 —
IBSRELA
  • Ardelyx, Inc. $90
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

529 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record